2. Metabolic Enzyme/Protease
  3. Lactate Dehydrogenase Aminotransferases (Transaminases)
  4. Sodium glycolate, 98%

Sodium glycolate, 98%  (Synonyms: Sodium hydroxyacetate, 98%)

Cat. No.: HY-W088011B Purity: 98.0%
COA
SDS
Handling Instructions Technical Support

Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt. Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria.

For research use only. We do not sell to patients.

Sodium glycolate, 98%

Sodium glycolate, 98% Chemical Structure

CAS No. : 2836-32-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in Water In-stock
Solid
10 g In-stock
25 g In-stock
50 g In-stock
> 100 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Sodium glycolate, 98% Related Antibodies

Top Publications Citing Use of Products

View All Aminotransferases (Transaminases) Isoform Specific Products:

View All Isoforms
GPT/ALT GOT/AST

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt. Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria[1][2].

In Vivo

Sodium glycolate (50 mg/100 g body weight/day; p.o.; daily; 7 days) significantly increases liver GAO and liver/kidney LDH activities, significantly reduces liver protein content, kidney protein content, and kidney GAD activity, directionally reduces liver GAD activity, and increases liver weight, relative to normal controls in male adult Wistar rats[1].
Sodium glycolate, 98% (100 mg per 100 g body weight/24 hr; p.o.; daily; 6 weeks) induces significant hyperoxaluria in male Wistar rats, alongside hypocalciuria and reduced transaminase activities in liver, kidney, and erythrocytes[2].
Sodium glycolate, 98% (100 mg per 100 g body weight/24 hr; p.o.; daily; 6 weeks) co-administered with pyridoxine induces significant hyperoxaluria in male Wistar rats, alongside hypocalciuria, increased urinary citrate excretion, and partially restored kidney transaminase activities relative to sodium glycolate-only treatment[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar (male, 4 months old)[1]
Dosage: 50 mg/100 g body weight/day
Administration: p.o.; daily; 7 days
Result: Significantly increased liver weight relative to normal controls.
Significantly increased liver weight/100 g body weight relative to normal controls.
Significantly lowered liver protein to 174 mg/g relative to normal controls.
Did not significantly change kidney weight and kidney weight/100 g body weight relative to normal controls.
Significantly lowered kidney protein to 212 mg/g relative to normal controls.
Significantly increased liver LDH activity to 3.71 U/mg protein relative to normal controls.
Significantly increased liver GAO activity to 1.33 U/mg protein relative to normal controls.
Directionally reduced liver GAD activity to 1.86 × 10-2 U/mg protein, with no statistically significant difference relative to normal controls.
Significantly increased kidney LDH activity to 3.67 U/mg protein relative to normal controls.
Significantly reduced kidney GAD activity to 0.18 × 10-2 U/mg protein relative to normal controls.
Animal Model: Wistar (male, 200 g body weight)[2]
Dosage: 100 mg per 100 g body weight/24 hr
Administration: p.o.; daily; 6 weeks
Result: Increased urinary oxalate levels to 55 mg/dg creatinine at week 1, 36 mg/dg creatinine at week 2, 44 mg/dg creatinine at week 4, and 36 mg/dg creatinine at week 5, compared to a basal level of 19 mg/dg creatinine.
Decreased urinary calcium excretion to 37 mg/dg creatinine at week 1, 14 mg/dg creatinine at week 3, 35 mg/dg creatinine at week 4, 18 mg/dg creatinine at week 5, and 35 mg/dg creatinine at week 6, compared to a basal level of 100 mg/dg creatinine.
Reduced liver glutamate-oxaloacetate transaminase (GOT) activity to 8.29 μmoles pyruvate produced/min/mg protein × 10-2.
Reduced kidney GOT activity to 6.06 μmoles pyruvate produced/min/mg protein × 10-2 and kidney glutamate-pyruvate transaminase (GPT) activity to 0.37 μmoles pyruvate produced/min/mg protein × 10-2.
Reduced erythrocyte GOT activity to 0.29 μmoles pyruvate produced/min/mg protein × 10-2.
Caused a slight, insignificant increase in body weight (from 199 g to 242 g) over 6 weeks, with no significant changes in liver weight (5.7 g), kidney weight (1.6 g), liver protein content (159 mg/g tissue), or kidney protein content (154 mg/g tissue) relative to pyridoxine-supplemented sodium glycolate-treated rats.
Animal Model: Wistar (male, 200 g body weight)[2]
Dosage: 100 mg per 100 g body weight/24 hr (sodium glycolate); 10 mg per 100 g body weight/24 hr (pyridoxine)
Administration: p.o.; daily; 6 weeks
Result: Increased urinary oxalate levels to 50 mg/dg creatinine at week 1, 30 mg/dg creatinine at week 2, and 32 mg/dg creatinine at week 4, compared to a basal level of 19 mg/dg creatinine.
Decreased urinary calcium excretion to 22 mg/dg creatinine at week 1, 26 mg/dg creatinine at week 3, 32 mg/dg creatinine at week 4, 26 mg/dg creatinine at week 5, and 32 mg/dg creatinine at week 6, compared to a basal level of 100 mg/dg creatinine.
Increased urinary citrate excretion to 372 mg/dg creatinine at week 2, 369 mg/dg creatinine at week 3, and 466 mg/dg creatinine at week 6, compared to a basal level of 227 mg/dg creatinine.
Caused a slight, insignificant increase in body weight (from 185 g to 245 g) over 6 weeks, with no significant changes in liver weight (5.9 g), kidney weight (1.6 g), liver protein content (191 mg/g tissue), or kidney protein content (151 mg/g tissue) relative to sodium glycolate-only treated rats.
Molecular Weight

98.03

Formula

C2H3NaO3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OCC(O[Na])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, stored under nitrogen, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL (1020.10 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 10.2010 mL 51.0048 mL 102.0096 mL
5 mM 2.0402 mL 10.2010 mL 20.4019 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 10.2010 mL 51.0048 mL 102.0096 mL 255.0240 mL
5 mM 2.0402 mL 10.2010 mL 20.4019 mL 51.0048 mL
10 mM 1.0201 mL 5.1005 mL 10.2010 mL 25.5024 mL
15 mM 0.6801 mL 3.4003 mL 6.8006 mL 17.0016 mL
20 mM 0.5100 mL 2.5502 mL 5.1005 mL 12.7512 mL
25 mM 0.4080 mL 2.0402 mL 4.0804 mL 10.2010 mL
30 mM 0.3400 mL 1.7002 mL 3.4003 mL 8.5008 mL
40 mM 0.2550 mL 1.2751 mL 2.5502 mL 6.3756 mL
50 mM 0.2040 mL 1.0201 mL 2.0402 mL 5.1005 mL
60 mM 0.1700 mL 0.8501 mL 1.7002 mL 4.2504 mL
80 mM 0.1275 mL 0.6376 mL 1.2751 mL 3.1878 mL
100 mM 0.1020 mL 0.5100 mL 1.0201 mL 2.5502 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sodium glycolate, 98% Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sodium glycolate, 98%2836-32-0Sodium hydroxyacetate, 98%Lactate DehydrogenaseAminotransferases (Transaminases)LDHglutamate-pyruvate transaminaseglycolate dehydrogenasemale Wistar ratslactate dehydrogenasemale albino ratsglycolate oxidasecalcium oxalate urinary stone formationoxalate biosynthesishyperoxaluriaglutamate-oxaloacetate transaminaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sodium glycolate, 98%
Cat. No.:
HY-W088011B
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.